Mankind Pharma Limited has submitted a regulatory disclosure under SEBI Listing Regulations (Regulation 30, 51 and other applicable provisions) regarding the completion of security cover realignment for its Non-Convertible Debentures (NCDs).
Key Actions and Approvals
The company received requisite approvals from NCD holders on July 13, 2026, followed by approval from BSE Limited on July 21, 2026. Following these approvals, the company created revised security in favor of the Debenture Trustee, Catalyst Trusteeship Limited, over tangible and intangible assets of the company and/or its subsidiaries.
Share Pledge Release
Consequent to the creation of the revised security cover, the pledge on 28,280 equity shares of Bharat Serums and Vaccines Limited (BSVL) has been released on August 17, 2026. These shares constituted 38.68% of the paid-up equity share capital of BSVL and were previously pledged in favor of the Debenture Trustee on behalf of the NCD holders.
Current Security Status
The revised security cover now stands at 1.26 times the amount of outstanding NCDs as of the disclosure date. No shares of BSVL remain under pledge for the NCDs following this realignment.